Related Experiment Video
Updated: Feb 26, 2026

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
Published on: August 1, 2025
Medical Cannabis Use in France: An Observational Safety Study Based on the RECANN Registry and the
Cécile Chevallier1, Anne Batisse2, Emilie Monzon3
1Centre d'Evaluation et d'Information sur la Pharmacodépendance, Hospices Civils de Lyon, Lyon, France.
Introduction:
The French National Agency for Medicines and Health Products Safety implemented in 2021 a nationwide experimentation for medical cannabis (MC), designed to assess the feasibility of implementing a new public health policy. A dedicated registry was established to support the notification of adverse drug reactions (ADRs). The objective of this study was to describe the safety data collected during the first 3 years of experimentation.
Method:
Data related to MC use were extracted from the registry and the French pharmacovigilance and addictovigilance database between March 26, 2021, and March 31, 2024.
Result:
Among the 3164 included patients, at least one ADR was reported in 1186 patients, including 81 patients (3%) with serious ADRs (SADRs). The most common ADRs were neurological (37.2%), gastrointestinal (16.9%), and psychiatric (15.2%). Among SADRs, six cases of acute coronary syndromes were reported, along with eight cases of suicidal thoughts including one suicide attempt. Half of these psychiatric events occurred in patients without a prior psychiatric history, and no cases of psychosis were documented. Regarding addictovigilance, only 12 ADRs were analyzed: seven withdrawal syndromes, three cases of tolerance, and two cases of THC-containing inflorescence misuse, including one case of MC use disorder.
Discussion:
During the experimentation, 3% of patients treated with MC experienced at least one serious ADR. The safety profile was dominated by neurological, gastrointestinal, and psychiatric ADRs. Only one case of MC misuse was identified with inflorescences. This study is observational and non-comparative and cannot provide a comprehensive assessment of the risk associated with MC use.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Drug Regulation
Clinical Trials
There are four phases in a clinical trial. A phase one...
Bioavailability Study Design: Healthy Subjects Versus Patients
Therapeutic Drug Monitoring: Affecting Factors

